Oncocyte Announces Additional Favorable Data Regarding Its Lead Assay VitaGraft, Which Was Published In The Journal, Nephrology Dialysis Transplantation
Oncocyte Announces Additional Favorable Data Regarding Its Lead Assay VitaGraft, Which Was Published In The Journal, Nephrology Dialysis Transplantation
Oncocyte宣布其主要检测VitaGraft的额外有利数据，这些数据已在《肾脏病透析移植》期刊上发表。
- Oncocyte first to published randomized interventional data to rule-in for biopsy in high-risk patient population
- Study shows that monitoring with Oncocyte's assay significantly reduces time to rejection diagnosis in patients with newly developed donor-specific antibodies
- Early detection of transplant rejection is growing in significance as novel therapeutic treatments show promising early results in antibody mediated rejection.
- Study published in Nephrology Dialysis Transplantation
- Oncocyte 首先发布了随机干预数据，以确定在高风险患者群体中进行活检的必要性。
- 研究表明，使用 Oncocyte 的检测显著缩短了新发展出供体特异性抗体患者的拒绝诊断时间。
- 随着新型治疗方法在抗体介导的排斥反应中显示出有希望的早期效果，早期发现移植排斥反应的重要性日益增长。
- 研究发布在《肾脏病透析移植》期刊上。
IRVINE, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp., (NASDAQ:OCX), a diagnostics technology company, today announced additional favorable data regarding its lead assay VitaGraft, which was published in the journal, Nephrology Dialysis Transplantation.
加利福尼亚州尔湾，2024年12月02日（GLOBE NEWSWIRE）-- Oncocyte corp.（纳斯达克：OCX），一家诊断科技公司，今天宣布了关于其主要检测VitaGraft的更多有利数据，该数据已发表在《肾脏病透析移植》期刊上。
热门讨论
FOMC维持利率但不确定性高企：美股后市走向如何？
🎙️讨论 1. 美联储强调政策路径存在“高度不确定性”，你更关注利率预期变化还是经济数据对市场的短期影响？ 2. 若核心通胀维持高位，哪类板块更具交易机会——防御型股票还是科技成长股？
Moo Live
03/20 02:25
联邦公开市场委员会新闻发布会，2025年3月19日